$TRDA
Entrada Therapeutics, Inc. Stock $trda

$trda Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000168937522000013 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.978M	$7.334M	$6.433M
YoY Change	81.2%	39.67%
% of Gross Profit
Research & Development	$18.96M	$16.25M	$15.72M
YoY Change	80.33%	137.93%	152.58%
% of Gross Profit
Depreciation & Amortization	$500.0K	$500.0K	$400.0K
YoY Change	66.67%	66.67%	100.0%
% of Gross Profit
Operating Expenses	$25.94M	$23.58M	$22.15M
YoY Change	80.56%	137.96%	163.92%
Operating Profit	-$25.94M	-$23.58M	-$22.15M
YoY Change	80.56%	137.96%	163.92%
Interest Expense	$799.0K	$403.0K	$480.0K
YoY Change	-1310.61%	1731.82%
% of Operating Profit
Other Income/Expense, Net	$799.0K	$403.0K	$480.0K
YoY Change	-1310.61%	4377.78%	3592.31%
Pretax Income	-$25.14M	-$23.18M	-$21.67M
YoY Change	74.2%	26.79%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$25.14M	-$23.18M	-$21.67M
YoY Change	74.2%	134.11%	158.6%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.80	-$0.74	-$0.69
Diluted Earnings Per Share	-$0.80	-$0.74	-$0.69
COMMON SHARES
Basic Shares Outstanding	31.37M shares	31.28M shares	31.25M shares
Diluted Shares Outstanding	31.30M shares	31.28M shares	31.25M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$215.6M	$244.3M	$263.9M
YoY Change	76.45%	78.36%
Cash & Equivalents	$53.31M	$90.87M	$84.64M
Short-Term Investments	$162.3M	$153.4M	$179.3M
Other Short-Term Assets	$19.16M	$9.649M	$8.810M
YoY Change	1316.19%	1300.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$234.7M	$253.9M	$272.7M
YoY Change	90.03%	84.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.444M	$7.785M	$7.197M
YoY Change	26.15%	53.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$954.0K	$875.0K	$1.434M
YoY Change	-67.87%	10.62%
Total Long-Term Assets	$39.73M	$42.01M	$43.99M
YoY Change	347.91%	614.77%
TOTAL ASSETS
Total Short-Term Assets	$234.7M	$253.9M	$272.7M
Total Long-Term Assets	$39.73M	$42.01M	$43.99M
Total Assets	$274.5M	$295.9M	$316.7M
YoY Change	107.31%	106.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.341M	$4.622M	$2.931M
YoY Change	-41.13%	145.72%
Accrued Expenses	$11.95M	$5.341M	$4.524M
YoY Change	144.9%	105.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.55M	$18.08M	$15.43M
YoY Change	201.08%	298.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$19.69M	$21.80M	$23.89M
YoY Change	5760.54%	4234.19%
Total Long-Term Liabilities	$19.69M	$21.80M	$23.89M
YoY Change	5760.54%	4234.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.55M	$18.08M	$15.43M
Total Long-Term Liabilities	$19.69M	$21.80M	$23.89M
Total Liabilities	$41.24M	$39.88M	$39.31M
YoY Change	450.13%	691.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$163.7M	-$138.5M	-$115.3M
YoY Change	117.69%
Common Stock	$3.000K	$3.000K	$3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$233.2M	$256.0M	$277.4M
YoY Change
Total Liabilities & Shareholders Equity	$274.5M	$295.9M	$316.7M
YoY Change	107.31%	106.19%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$25.14M	-$23.18M	-$21.67M
YoY Change	74.2%	134.11%	158.6%
Depreciation, Depletion And Amortization	$500.0K	$500.0K	$400.0K
YoY Change	66.67%	66.67%	100.0%
Cash From Operating Activities	-$27.48M	-$18.01M	-$20.99M
YoY Change	95.25%	10.85%	151.81%
INVESTING ACTIVITIES
Capital Expenditures	-$810.0K	-$775.0K	$594.0K
YoY Change	0.5%	-68.39%	-34.58%
Acquisitions
YoY Change
Other Investing Activities	-$9.324M	$25.00M	-$180.9M
YoY Change
Cash From Investing Activities	-$10.13M	$24.22M	-$181.5M
YoY Change	1157.32%	-1087.97%	19892.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	60.00K	11.00K	$50.00K
YoY Change	-43.4%	-99.99%	-99.96%
NET CHANGE
Cash From Operating Activities	-27.48M	-18.01M	-$20.99M
Cash From Investing Activities	-10.13M	24.22M	-$181.5M
Cash From Financing Activities	60.00K	11.00K	$50.00K
Net Change In Cash	-37.56M	6.227M	-$202.5M
YoY Change	154.19%	-93.64%	-288.98%
FREE CASH FLOW
Cash From Operating Activities	-$27.48M	-$18.01M	-$20.99M
Capital Expenditures	-$810.0K	-$775.0K	$594.0K
Free Cash Flow	-$26.67M	-$17.23M	-$21.59M
YoY Change	101.01%	24.94%	133.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001689375
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40969
	dei	Entity Registrant Name EntityRegistrantName	ENTRADA THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3983399
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6 Tide Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02210
	dei	City Area Code CityAreaCode	857
	dei	Local Phone Number LocalPhoneNumber	520-9158
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	TRDA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31368470	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90867000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291064000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	153387000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9649000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7636000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	253903000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	298700000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7785000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6261000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3950000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29404000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	875000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	872000	usd
CY2022Q2	us-gaap	Assets Assets	295917000	usd
CY2021Q4	us-gaap	Assets Assets	305833000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4622000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	706000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5341000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6013000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8114000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	18077000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6719000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21801000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	usd
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	396000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	39878000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7115000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31366242	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31284448	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31336092	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31224336	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	396820000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	392384000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2265000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138519000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93669000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	256039000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298718000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	295917000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	305833000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16248000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6829000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31966000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13052000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7334000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3081000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13767000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5251000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	23582000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	9910000	usd
	us-gaap	Operating Expenses OperatingExpenses	45733000	usd
	us-gaap	Operating Expenses OperatingExpenses	18303000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23582000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9910000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-45733000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18303000	usd
CY2022Q2	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	403000	usd
CY2021Q2	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	9000	usd
	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	883000	usd
	trda	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	22000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	403000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	883000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-23179000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-9901000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-44850000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-18281000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.56
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.56
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.16
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31275306	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31275306	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1309535	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1309535	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31261189	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31261189	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1290690	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1290690	shares
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-730000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2265000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-730000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2265000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23909000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9901000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47115000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18281000	usd
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	85299885	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	81658000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-41490000	usd
CY2021Q1	trda	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	53522099	shares
CY2021Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	115831000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2021Q1	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	8000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	164000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8380000	usd
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	138821984	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	197489000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-49669000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	212000	usd
CY2021Q2	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	18000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	326000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-9901000	usd
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	138821984	shares
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	197489000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-59014000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	298718000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000	usd
CY2022Q1	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	35000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1794000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1535000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21671000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	277391000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	usd
CY2022Q2	trda	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	34000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2512000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-730000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-23179000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	256039000	usd
	us-gaap	Profit Loss ProfitLoss	-44850000	usd
	us-gaap	Profit Loss ProfitLoss	-18281000	usd
	us-gaap	Depreciation Depreciation	856000	usd
	us-gaap	Depreciation Depreciation	451000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4306000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	490000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-287000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2508000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-215000	usd
	trda	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-3587000	usd
	trda	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-14000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	3601000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	231000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-800000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	73000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3473000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	usd
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	561000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16246000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1369000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2452000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	182653000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	26714000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-157308000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2452000	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	115831000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	61000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	241000	usd
	trda	Proceeds From Early Exercise Of Stock Options ProceedsFromEarlyExerciseOfStockOptions	0	usd
	trda	Proceeds From Early Exercise Of Stock Options ProceedsFromEarlyExerciseOfStockOptions	528000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116600000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-196247000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	97902000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291064000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39045000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94817000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136947000	usd
	trda	Deferred Financing Costs In Accounts Payable And Accrued Expenses DeferredFinancingCostsInAccountsPayableAndAccruedExpenses	0	usd
	trda	Deferred Financing Costs In Accounts Payable And Accrued Expenses DeferredFinancingCostsInAccountsPayableAndAccruedExpenses	264000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	667000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	369000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	32991000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	495000	usd
	trda	Transfer Of Deposits For Equipment From Operating To Investing Cash Flows TransferOfDepositsForEquipmentFromOperatingToInvestingCashFlows	0	usd
	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	69000	usd
	trda	Vesting Of Options Early Exercised Subject To Repurchase VestingOfOptionsEarlyExercisedSubjectToRepurchase	26000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-44900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-18300000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138500000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	244300000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33000000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90867000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	291064000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	3950000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94817000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	291064000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	33400000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	155652000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2265000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	153387000	usd
CY2022Q2	trda	Number Of Securities NumberOfSecurities	33	security
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	153400000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10051000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7677000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2266000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1416000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7785000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6261000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	500000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	300000	usd
	us-gaap	Depreciation Depreciation	900000	usd
	us-gaap	Depreciation Depreciation	500000	usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.73
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2362000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4077000	usd
CY2022Q2	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	2192000	usd
CY2021Q4	trda	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	1032000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	339000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	419000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	448000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	485000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5341000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6013000	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8114953	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6583887	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2512000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	326000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4306000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	490000	usd
CY2022Q2	trda	Unvested Shares From Early Exercises UnvestedSharesFromEarlyExercises	81794	shares
CY2021Q4	trda	Unvested Shares From Early Exercises UnvestedSharesFromEarlyExercises	111756	shares
CY2022Q2	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	200000	usd
CY2021Q4	trda	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Nonvested Amount ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount	300000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	2295000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3461870	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.38
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1150523	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.04
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30150	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.01
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	46522	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4535721	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.59
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2471102	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.79
	us-gaap	Operating Lease Cost OperatingLeaseCost	4185000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	800000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9219000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9494000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Renewal Term1 LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1	P5Y
	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	2295000	usd
	us-gaap	Lease Cost LeaseCost	4185000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	4070000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0381
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4504000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8650000	usd
CY2022Q2	trda	Lessee Operating Lease Liability To Be Paid Due After Year Three LesseeOperatingLeaseLiabilityToBePaidDueAfterYearThree	0	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	31867000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1952000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	29915000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1	P10Y
CY2022Q1	trda	Operating Leases Rental Expenses Initial Fixed Monthly Rental Payments First12 Months OperatingLeasesRentalExpensesInitialFixedMonthlyRentalPaymentsFirst12Months	500000	usd
CY2022Q1	trda	Number Of Square Feet In Lease Agreement NumberOfSquareFeetInLeaseAgreement	65000	sqft
CY2022Q1	trda	Operating Leases Rental Expenses Annual Increase OperatingLeasesRentalExpensesAnnualIncrease	0.03
CY2022Q1	trda	Tenant Improvements Allowance TenantImprovementsAllowance	19500000	usd
CY2022Q1	trda	Initial Fixed Rental Income Per Rentable Square Foot Of Premises Per Annum InitialFixedRentalIncomePerRentableSquareFootOfPremisesPerAnnum	240.00
CY2022Q1	trda	Operating Leases Additional Allowance OperatingLeasesAdditionalAllowance	1600000	usd
CY2022Q1	trda	Tenant Allowance Rentable Square Foot Of Premises Per Annum TenantAllowanceRentableSquareFootOfPremisesPerAnnum	20.00
CY2022Q1	trda	Interest Rate For Additional Improvements Allowance InterestRateForAdditionalImprovementsAllowance	0.08
CY2022Q2	trda	Operating Lease Related Expenses Prior To Commencement OperatingLeaseRelatedExpensesPriorToCommencement	3200000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-23179000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-9901000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-44850000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-18281000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31275306	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31275306	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1309535	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1309535	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31261189	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31261189	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1290690	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1290690	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.56
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.56
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.16
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4912619	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21562599	shares

Files In Submission

Name	View Source	Status
0001689375-22-000013-index-headers.html	Edgar Link	pending
0001689375-22-000013-index.html	Edgar Link	pending
0001689375-22-000013.txt	Edgar Link	pending
0001689375-22-000013-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trda-20220630.htm	Edgar Link	pending
trda-20220630.xsd	Edgar Link	pending
trda-20220630x10qex311.htm	Edgar Link	pending
trda-20220630x10qex312.htm	Edgar Link	pending
trda-20220630x10qex321.htm	Edgar Link	pending
trda-20220630_pre.xml	Edgar Link	unprocessable
trda-20220630_cal.xml	Edgar Link	unprocessable
trda-20220630_lab.xml	Edgar Link	unprocessable
trda-20220630_htm.xml	Edgar Link	completed
trda-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRDA
Entrada Therapeutics, Inc. Stock $trda

2022 Q3 Form 10-Q Financial Statement

#000168937522000013 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA Entrada Therapeutics, Inc. Stock $trda

2022 Q3 Form 10-Q Financial Statement

#000168937522000013 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRDA
Entrada Therapeutics, Inc. Stock $trda